Key Takeaways
- 20% revenue growth, guidance raised: Q1 FY27 revenue grew 20% YoY, and with the new strategic manufacturing agreement in place, management now targets ~20% growth over the next 4 years, up from a prior 15% CAGR.
- A landmark end-to-end contract: The 55-SKU sterilized injectables agreement with a leading global pharma company, spanning 3 sites and covering oncology and non-oncology products, is the quarter's defining event and validates the Cenexi acquisition.
- CDMO is now half the business: CDMO revenue grew 20% YoY and contributed 50% of total revenues; management sees CDMO becoming larger than B2B by CY29.
- Margins expanded sharply: Adjusted EBITDA margin improved to 28% from 25% YoY, with management targeting 30% near-term and 35% in 3–4 years.
- What to watch next quarter: Whether the bag line FDA approval lands by August/September, which could push current-year growth above 15%, and clarity on the 4-year growth outlook after evaluating other contracts under discussion.
The Strategic Manufacturing Agreement
- What was signed: A technology transfer, manufacturing, and supply agreement with a leading global specialty pharma company for a portfolio of 55 sterilized injectable SKUs across vials, lyophilized products, ampoules, and prefilled syringes. The portfolio spans oncology and non-oncology products across 3 sites, with scope to add more products.
- Revenue timing: Tech transfer starts September of this year, with the first set of products transferred in 24 months and filings every quarter. Revenue generation is anticipated from calendar year 2029, with ramp-up through CY29–CY30 and the entire portfolio expected launched by CY30.
- Revenue potential: Once all products are commercialized, revenue potential is expected to be approximately USD9 crore to USD10 crore, with scope to add more products soon.
- Cenexi's role: Cenexi will warehouse certain products, package a few, and perform final QP release for the European market. Management credits the acquisition as essential to winning the deal.
Ravi Mitra: "To be fair, without Cenexi, this wouldn't have happened in a way. So that also strengthens our strategic initiative when we acquired Cenexi because otherwise, we couldn't have provided the full best solution for the partner."
- Why big pharma is interested: Companies face a 5–6x cost differential between European and Indian sites, and moving branded products to U.S. manufacturing destroys operational leverage. Gland's pitch is an end-to-end solution across 3–4 sites under one company with breadth of platforms.
- More to come: Management is actively pursuing similar end-to-end contracts with big pharma, and will have more clarity on the 4-year growth outlook by September/October after evaluating other contracts under discussion.
CDMO & B2B Performance
| Segment | Growth | Commentary |
|---|---|---|
| CDMO | ▲ 20% YoY | 50% of total revenue; driven by recent product launches and progression of existing commercial programs. |
| B2B | ▲ 19% YoY | Increased demand from existing customers, new contract wins, higher volumes, and supply reliability enabling market share expansion. |
| US | ▲ 32% YoY | Recent CDMO launches plus volume expansion; MVI and Dalbavancin ramping as expected. |
| Europe & other regulatory | ▲ 11% YoY | Increasing customer engagement, launch contributions, improving CDMO momentum. |
| ROW | ▬ Flat | Demand healthy but Saudi Arabia supply disruptions and delayed NUPCO tenders weighed. |
- Base business strength: Ex-Cenexi, the base business grew 24%, with U.S. growing 32%. Forex contributed ~5 percentage points, so constant currency growth was ~19–20%.
- U.S. outperformance is structural: Gland's U.S. growth consistently exceeds market growth of ~3–4% because of new launches and a better cost structure that enables share capture from competitors.
- CDMO mix trajectory: Near-term target is 30% CDMO on a consolidated basis, moving to roughly 50-50 CDMO/B2B within 2 years, and CDMO potentially larger than B2B by CY29.
- Cenexi Q1 disruption: The French summer heat wave delayed quality releases at Cenexi, pushing some revenue into Q2. Cenexi EBITDA improved to 4% from 2% last year, in line with guidance.
- Cenexi guidance maintained: Near €20 crore revenue and high single-digit margins for FY27, with double-digit EBITDA by year-end.
Srinivas Sadu: "We looked at opportunity where probably everybody is saying that there's no money in generics, but we're saying, okay, we -- our strength is in manufacturing and quality, why can't we leverage that to offer these services so that they'll be more competitive."
New Collaborations & Pipeline
- Neuland Laboratories collaboration: Strategic collaboration for manufacture of sterile APIs for microparticle depot products, strengthening complex injectable capabilities. Gland is building a dedicated block for Neuland; currently manufacturing 2 APIs with another 5–6 products in the category needing expansion.
- GLP-1 contract signed: A new contract this quarter covers both semaglutide and tirzepatide for U.S. and EU markets, with transfer activities to begin in the next quarter or two.
- GLP-1 revenue visibility is limited: Management has no clear visibility on front-end approval status, so near-term revenue assumptions are limited to tech-transfer fees. Major U.S. volume is expected in FY30–31.
Srinivas Sadu: "We don't have a clear visibility on the front-end approval status for these products. So it's very difficult to assume the numbers for them. So that's why we're keeping close to our chest how that pans out, but that will be an upside if it pans out well."
- Liposomal in-licensing: Agreement with a China-based development company for a niche liposomal product for U.S. and European markets, with potential to extend beyond a single product. The product is already developed and approved in China using an EU RLD; Gland will invest in a compounding suite, technology transfer, and a BE study before filing in the U.S. Revenue contribution expected from FY30, with the product estimated at $300 crore over the next 3 years.
- GLP-1 Canada upside: One customer has filed in Canada, with potential launch in the last quarter of this year, which could be upside.
- Complex products are the next growth driver: Big products, especially microspheres, are post-FY29 and at various stages from clinical to exhibit. Most complex products will take a larger chunk of U.S. business after FY29.
- NDDS project: Timeline is commercialization in 2029, with revenue potential of $2.5–3 crore.
Margins & Profitability
| Metric | Q1 FY27 | YoY Change |
|---|---|---|
| Gross margin | 65% | Favorable product mix, higher CDMO contribution, operational efficiencies, procurement initiatives, yield improvement. |
| Adjusted EBITDA margin | 28% | Up from 25%; driven by higher CDMO revenue, favorable mix, operating leverage, productivity, cost optimization. |
| PAT | — | +47% YoY; sequential decline vs Q4 FY26 due to forex loss vs prior-quarter forex gain. |
| R&D spend | — | +16% YoY; focused on complex injectable peptides, depot products, drug delivery, liposomal products. |
| Cash flow from operations | ₹318.3 crore | Strong operating performance and disciplined working capital management. |
- EBITDA trajectory: Near-term target is 30% consolidated EBITDA, with a mid-to-long-term target of 35% in the next 3–4 years once CDMO contracts are on track.
- Profit share: Profit share this quarter was about 9%.
- Capex program underway: Execution commenced on the ₹2,000 crore capex program, with FY27 spend planned at ~₹550 crore, scaling up as brownfield construction begins.
- Isolator line investment: ~₹165 crore invested in an isolator line in the oncology plant, with installation in January of this year.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | ~20% growth over next 4 years, up from prior 15% CAGR | FY27–FY30 |
| Current-year growth | 15% constant currency growth "clearly achievable"; could exceed 15% if bag line FDA approval lands by August/September | FY27 |
| Strategic agreement revenue | Revenue generation anticipated from calendar year 2029; entire portfolio launched by CY30 | CY29–CY30 |
| Strategic agreement revenue potential | Approximately $9–10 crore once all products commercialized | By CY30 |
| CDMO mix | 30% CDMO near-term; ~50-50 CDMO/B2B in 2 years; CDMO larger than B2B by CY29 | Near-term to CY29 |
| EBITDA margin | 30% near-term; 35% in 3–4 years | Near-term to FY30–31 |
| Cenexi guidance | Near €20 crore revenue, high single-digit margins for FY27; double-digit EBITDA by year-end | FY27 |
| Liposomal product revenue | Meaningful contribution expected from FY30; product estimated at $300 crore over next 3 years | FY30 onward |
| GLP-1 revenue | Very limited over next 3 years; major U.S. volume in FY30–31 | FY30–31 |
| Complex products contribution | Most complex products post-FY29; next growth driver after the 4-year 20% growth period | Post-FY29 |
| Fontenay ampoule line | New high-capacity line enters production in early 2027; adds ~3 crore ampoules annual capacity | Early 2027 |
| Cenexi growth capex | New block with vial and lyos at BLA, high-speed ampoule line at Fontenay to finish by end of next year | End of FY28 |
| NUPCO tenders | Award delayed; results expected shortly | Undated |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹1,800.3 crore, +20% YoY |
| Adjusted EBITDA | ₹510.2 crore, adjusted EBITDA margin 28% |
| Reported EBITDA | ₹493 crore, EBITDA margin 27%, vs 24% in Q1 FY26 |
| Profit after tax | ₹317 crore, +47% YoY, PAT margin 18% |
| Gross margin | 65%, supported by favorable product mix and CDMO contribution |
| CDMO revenue | ₹891.5 crore, +20% YoY, 50% of total revenues |
| B2B revenue | ₹908.8 crore, +19% YoY, 50% of total revenues |
| US revenue | ₹981 crore, +32% YoY |
| Europe and other regulatory markets revenue | ₹448.8 crore, +11% YoY |
| Rest of world revenue | ₹303.9 crore, broadly in line with corresponding period last year |
| India revenue | ₹66.6 crore |
| R&D spend | ₹77.2 crore, ~4% of consolidated revenue, +16% YoY |
| Forex loss | ₹3.6 crore, vs forex gain of ₹50.8 crore in Q4 FY26 and ₹3.9 crore in Q1 FY26 |
| Other income | ₹61.2 crore, primarily interest income |
| Effective tax rate | ~27% |
| Cash and cash equivalents | ₹3,546.6 crore as of June 30, 2026 |
| Net cash position | ₹3,293.9 crore |
| Cash flow from operations | ₹318.3 crore |
| Capital expenditure | ₹113.2 crore in Q1; FY27 planned spend ~₹550 crore |
| Cenexi revenue | EUR 4.8 crore, EBITDA EUR 0.2 crore |
| US filings and approvals | 3 ANDAs filed, 7 approvals received, 4 products launched |
| Strategic manufacturing agreement | 55 SKUs across 3 sites, revenue potential ~$9–10 crore, revenues expected from CY2029 |
| Constant currency growth | 15% for Q1 consol; 15% "clearly achievable" for FY27 |
| Growth outlook | ~20% growth next 4 years with new contract in place |
| Profit share | ~9% of revenue this quarter |
| NDDS project | Revenue potential $2.5–3 crore, timeline '28, commercialize '29 |